Navigation Links
AbbVie's Investigational HCV Regimen Receives Breakthrough Therapy Designation from the U.S. Food and Drug Administration
Date:5/6/2013

. Leonard , M.D., senior vice president and chief scientific officer, AbbVie. "Our HCV program is one part of our advancing pipeline which is focused on delivering innovative therapies to address pressing areas of unmet clinical need."  

New results from Aviator were recently presented at the 2013 International Liver Congress® in Amsterdam. These results continued to demonstrate high SVR rates against GT1 HCV with the 12-week, triple-DAA regimen with ribavirin, across patient types. Specifically,

  • 99 percent of treatment-naive patients (n=79) achieved SVR12, 96 percent achieved SVR24 in an intent-to-treat analysis
  • 93 percent of prior null responders (n=45) achieved SVR12 and SVR24
  • A single relapse with this regimen occurred at post-treatment week two
  • Of the 247 patients treated for 12 and 24 weeks with triple DAA with ribavirin, four patients (1.6 percent) discontinued the study because of drug-related adverse events. Serious adverse events were noted in four patients (1.6 percent), with one (arthralgia) considered possibly drug-related. Other events reported in more than 10 percent of patients included headache, fatigue, nausea, insomnia, and diarrhea. Grade 3-4 laboratory abnormalities in total bilirubin (six patients) and ALT (one patient) were noted; all resolved with continued dosing.
  • AbbVie's all-oral, triple-DAA combination is currently being studied in Phase 3 clinical trials. The Phase 3 program includes more than 2,000 patients with HCV genotype 1, with trial sites in 29 countries. The DAAs in the studies include ABT-450/r (protease inhibitor and ritonavir), ABT-267 (NS5A inhibitor) and ABT-333 (non-nucleoside polymerase inhibitor). Treatment durations under investigation are 12 weeks in non-cirrhotic patients, and 12 or 24 weeks in cirrhotic patients. All patients will be followed for 48 weeks post-treatment. Co
    '/>"/>

    SOURCE AbbVie
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine technology :

    1. Bayer Initiates Phase III Trial of Investigational Inhaled Amikacin Solution (BAY41-6551T) in Mechanically Ventilated Patients with Gram-negative Pneumonia
    2. Bayers Investigational Riociguat Granted U.S. FDA Priority Review for Pulmonary Arterial Hypertension and Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension
    3. Positive Preclinical Data for NKTR-214, an Investigational Cancer Immunotherapy Targeting the IL-2 Receptor Complex, Presented at AACR Annual Meeting 2013
    4. European Medicines Agency accepts marketing authorization application for Boehringer Ingelheim and Eli Lilly and Companys empagliflozin*, an investigational type 2 diabetes treatment
    5. Boehringer Ingelheim and Eli Lilly and Company submit new drug application to FDA for empagliflozin, an investigational type 2 diabetes treatment
    6. Genocea Publishes Preclinical Data For Investigational Vaccine Candidate For HSV-2
    7. Noven Announces FDA Advisory Committee Vote on Investigational Low-Dose Mesylate Salt of Paroxetine (LDMP) for Vasomotor Symptoms Associated with Menopause
    8. Scioderms Investigational New Drug (IND) Application for SD-101 for Treatment of Epidermolysis Bullosa (EB) Allowed by the FDA
    9. BHR Pharma Investigational Traumatic Brain Injury Treatment Receives European Medicines Agency Orphan Medicinal Product Designation
    10. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
    11. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/18/2014)... MELBOURNE, Australia , Sept. 18, 2014 /PRNewswire/ ... the appointments of Dr. Ashraf Hanna , M.D., ... to its Board of Directors. Dr. Hanna is the ... Genentech and Chief Financial Officer for the Genentech Foundation, ... and Global Head of Business Development and Licensing for ...
    (Date:9/18/2014)... Relmada Therapeutics, Inc., (OTCQB: RLMD), a clinical-stage ... pain, announced today that it has appointed Mr. ... Director of Clinical Development. During his extensive ... led successful global clinical operations teams, in the US ... clinical development of numerous therapeutics and diagnostics across a ...
    (Date:9/18/2014)... /CNW/ - A new expert panel report, Improving Medicines ... released today by the Council of Canadian Academies, addresses ... children. Each year about half of Canada,s ... prescription drug. Much of this prescribing is done off-label ... potential health risks. Children have historically been ...
    Breaking Medicine Technology:Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 2Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 3Relmada Therapeutics, Inc. Appoints Christopher W. James As Senior Director of Clinical Development 2Studying medicines in children is always possible and is in their best interest, finds Expert Panel 2Studying medicines in children is always possible and is in their best interest, finds Expert Panel 3
    ... publication in prominent peer-reviewed journal highlights,findings of ... infection, EVANSTON, Ill., March 17 ... using a,rapid molecular diagnostic test is effective ... published in the Annals of Internal Medicine,by ...
    ... on Track to Initiate Phase 2b in Second Quarter ... - Conference Call Tomorrow at 8:00 a.m. ... Ardea Biosciences, Inc.,(Nasdaq: RDEA ) today announced positive ... RDEA806, its novel,investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), in,patients ...
    Cached Medicine Technology:Evanston Northwestern Healthcare Researchers Explain Effects of Large-Scale, Universal MRSA Surveillance Program That Supports Expanded Intervention 2Evanston Northwestern Healthcare Researchers Explain Effects of Large-Scale, Universal MRSA Surveillance Program That Supports Expanded Intervention 3Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load 2Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load 3Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load 4
    (Date:9/18/2014)... 18, 2014 After years of shooting at ... firing range berms were saturated with lead, which increased the ... in the berm and send metal fragments back at the ... splashback, and the greater the potential for injury to officers. ... to remove lead from the range environment. , ...
    (Date:9/18/2014)... September 18, 2014 Sutter Health’s California ... founder of Dolby Laboratories, by naming the Ray Dolby ... of Ray Dolby provided a founding gift of $21 ... which provides services to patients and families suffering from ... people have been treated at the center since its ...
    (Date:9/18/2014)... September 18, 2014 On August 23, ... Glenn with the Distinguished Service Award for his ... at the 2014 National Basketball Retired Players Association (NBRPA) ... drafted by the Chicago Bulls in 1977, Glenn would ... New York Knicks, the Atlanta Hawks, and the Milwaukee ...
    (Date:9/18/2014)... MD Complete , the breakthrough ... prescription, announced today that SHAPE Magazine has named ... Peel” in its annual Beauty Awards. The issue is ... products as tested by SHAPE’s expert team. , SHAPE ... Among the thousands of beauty products launched every year, ...
    (Date:9/18/2014)... September 18, 2014 Unitek ... by the Accrediting Commission of Career Schools and ... body awarded Unitek College’s community outreach efforts with ... in Community Service Award. , Unitek College ... service-learning opportunities through our Community OutReach Educational (CORE) ...
    Breaking Medicine News(10 mins):Health News:Firing Range Safety is Ohio DOC Priority 2Health News:Firing Range Safety is Ohio DOC Priority 3Health News:Sutter Health’s CPMC announces Ray Dolby Brain Health Center 2Health News:Sutter Health’s CPMC announces Ray Dolby Brain Health Center 3Health News:The HearStrong Foundation Recognizes Mike “Stinger” Glenn with the Distinguished Service Award at the 2014 Legends World Sports Conference 2Health News:The HearStrong Foundation Recognizes Mike “Stinger” Glenn with the Distinguished Service Award at the 2014 Legends World Sports Conference 3Health News:MD Complete Wins Shape Beauty Award for Best Peel 2Health News:Unitek College Receives Award for Community Service Initiatives 2Health News:Unitek College Receives Award for Community Service Initiatives 3Health News:Unitek College Receives Award for Community Service Initiatives 4
    ... lymph node metastasis in patients with pancreatico-biliary carcinoma has ... and shorter survival term. , This study, performed by ... Young Chul Kim, is described in a research article ... the World Journal of Gastroenterology. , The study evaluated ...
    ... ALLEGAN, Mich., May 20 Perrigo Company,(Nasdaq: ... Papa, Perrigo,s,Chairman and CEO will present at the ... May 21, at 10:00 a.m. (ET) at the ... the following link, http://www.veracast.com/webcasts/citigroup/healthcare08/25105341.cfm ., Perrigo ...
    ... May 20 Pennsylvania, along,with 28 other states ... million,settlement, the largest ever for a multi-state consumer ... advertising related to the,drug, Vioxx. Pennsylvania will receive ... Corbett said that in 1999, Merck allegedly,launched an ...
    ... May 20 Depression is a serious,but treatable health ... condition will be the focus of a national campaign ... Depression, which is,supported by the Anthem Blue Cross Foundation, ... Men Get Depression National Awareness Campaign is an effort ...
    ... life, it may be better than standard oxygen therapy, study ... suggests that a mechanical ventilator can ease suffering and help ... , A large percentage of these patients didn,t want to ... to wear an oxygen mask. But those who were willing ...
    ... Against Tobacco Recognized Nationally-, WASHINGTON, May 20 ... Regional Youth Advocate of the Year,by the Campaign for ... Michelle is being honored at a gala in the ... international grant winner,three other regional winners and a group ...
    Cached Medicine News:Health News:Pennsylvania Attorney General Corbett Announces a Multi-state, $58 Million Settlement With Merck Over Deceptive Advertising Concerning the Safety of Vioxx 2Health News:Anthem Blue Cross Foundation Supports National Campaign Focused on Depression Among Men 2Health News:Anthem Blue Cross Foundation Supports National Campaign Focused on Depression Among Men 3Health News:Ventilator Relieves Lung Cancer Pain in Final Hours 2Health News:Ventilator Relieves Lung Cancer Pain in Final Hours 3Health News:Campaign for Tobacco-Free Kids Honors Michelle Mays of Rhinelander, WI As Youth Advocate of the Year 2
    ... hands play an important part in our ... and rheumatic changes can cause severe handicaps. ... the finger-joint prostheses was to produce a ... natural function as nearly possible.,The cementless RM ...
    ... hands play an important part in our ... and rheumatic changes can cause severe handicaps. ... the finger-joint prostheses was to produce a ... natural function as nearly possible.,The cementless RM ...
    ... precise control of the thigh during varus/valgus manipulation ... the proximal thigh during ACL or PCL procedures. ... on both right and left legs and may ... Holder can be used with an Arthrex tourniquet ...
    ... for trauma, foot and ankle or deformity ... External Fixation components are designed to reduce ... the complexity of intra-operative and post-operative frame ... and hinges eliminate the need to stock ...
    Medicine Products: